Table 1 Baseline characteristics of patients enrolled in the study
Number of patients (percentage) | |
|---|---|
Number of patients | 20 |
Male | 16 (80%) |
Female | 4 (20%) |
ECOG status | |
ECOG 0 | 13 (65%) |
ECOG 1 | 7 (35%) |
Median age | 60 (47−71) |
Race | |
White | 19 (95%) |
Other | 1 (5%) |
Stage at presentation | |
Stage 2/3 | 8 (40%) |
Stage 4 | 12 (60%) |
Previous cancer therapies (any) | 18 (90%) |
Nephrectomy | 12 (60%) |
Previous radiation therapy | 8 (40%) |
Previous systemic therapy | 0 (0%) |
Pathology at presentation | |
Clear cell | 19 (95%) |
Unclassified | 1 (5%) |
Location of metastatic disease | |
Lung | 17 (85%) |
Renal fossa | 10 (50%) |
Bone | 4 (20%) |
Liver | 3 (15%) |
Brain | 4 (20%) |
Other | 5 (25%) |
IMDC prognostic factor | |
Favorable risk | 0 (0%) |
Intermediate/poor risk | 20 (100%) |
Treatment regimen | |
Ipilimumab/nivolumab | 16 (80%) |
Pembrolizumab/axitinib | 3 (15%) |
Pembrolizumab/lenvatinib | 1 (5%) |
